Picture of Consun Pharmaceutical logo

1681 — Consun Pharmaceutical News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareBalancedMid CapSuper Stock

China's Consun Pharmaceutical H1 revenue rises on sales network expansion

China's Consun Pharmaceutical H1 revenue rises on sales network expansion


Overview

  • China pharmaceutical maker's H1 revenue rose 13.8% yr/yr to RMB1.78 bln

  • Net profit attributable to shareholders increased 19.5% yr/yr; basic EPS up 20.3%

  • Company declared interim dividend of HKD0.38 per share and repurchased 2.6 mln shares


Outlook

  • Company did not provide specific financial guidance or outlook for future periods


Result Drivers

  • SALES NETWORK EXPANSION - Co said revenue growth was mainly driven by continued efforts to expand its sales network and broaden market coverage across China

  • PRODUCT MIX - Strong growth in kidney medicines and hepatobiliary medicines offset declines in medical contrast medium, orthopaedics and dermatologic medicines

  • HIGHER GROSS MARGIN - Co attributed margin improvement to supplier management optimization, production efficiency gains and lower key raw material prices


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Net Income Attributable

RMB 595.31 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Consun Pharmaceutical Group Ltd is HK$24.30, about 81.3% above its August 25 closing price of HK$13.40

  • The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago


Reuters Recommended Reads

  • Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales

  • Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost

  • Aug 25 - China's Weigao H1 profit falls 23% as price drops, competition hit margins


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Consun Pharmaceutical

See all news